Avaleht › Melanoom › Minnesota › Rochester
Melanoom kliinilised uuringud linnas Rochester, MN
16 uuringut haiguse Melanoom jaoks otsivad osalejaid linnas Rochester ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
VärbamineFaas 2
- Mayo Clinic in Rochester, Rochester
Pan-tumor MRD Study
VärbamineVaatlusuuring
- Mayo Clinic, Rochester
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
VärbamineFaas 2
- Local Institution - 0129, Rochester
- Local Institution - 0174, Rochester
- Local Institution - 0181, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
VärbamineVaatlusuuring
- Mayo Clinic (Rochester), Rochester
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
VärbamineFaas 1
- Mayo Clinic - Rochester, Rochester
Project: Every Child for Younger Patients With Cancer
VärbamineVaatlusuuring
- Mayo Clinic in Rochester, Rochester
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
VärbamineVaatlusuuring
- Mayo Clinic in Rochester, Rochester
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
Värbamine
- Mayo Clinic in Rochester, Rochester
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
VärbamineVaatlusuuring
- Mayo Clinic in Rochester, Rochester
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
VärbamineFaas 1/2
- Mayo Clinic Rochester, Rochester
Neoadjuvant Darovasertib in Primary Uveal Melanoma
VärbamineFaas 3
- Mayo Clinic - PPDS, Rochester
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
VärbamineFaas 2/3
- Mayo Clinic Rochester, Rochester
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
VärbamineVaatlusuuring
- Mayo Clinic, Rochester
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
VärbamineFaas 3
- Mayo Clinic Minnesota, Rochester
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
VärbamineFaas 3
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
VärbamineFaas 1/2
- Mayo Clinic in Minnesota, Rochester
Melanoom uuringud teistes linnades
- Houston, TX59 uuringut
- New York City, NY38 uuringut
- Los Angeles, CA34 uuringut
- Nashville, TN33 uuringut
- Pittsburgh, PA31 uuringut
- Boston, MA26 uuringut
- Philadelphia, PA23 uuringut
- San Francisco, CA22 uuringut
- Durham, NC21 uuringut
- Atlanta, GA21 uuringut
- St. Louis, MO21 uuringut
- Salt Lake City, UT21 uuringut
Muud uuringud linnas Rochester
- Rinnavähk42 uuringut
- Mitteväikerakuline kopsuvähk37 uuringut
- Metastaatiline vähk31 uuringut
- Vähk (kõik liigid)30 uuringut
- Käär- ja pärasoolevähk29 uuringut
- Munasarjavähk29 uuringut
- Müeloom24 uuringut
- Eesnäärmevähk22 uuringut
- Südamepuudulikkus22 uuringut
- Pankreasevähk22 uuringut
- Kopsuvähk20 uuringut
- Endomeetriumivähk20 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.